We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

AVTX Avalo Therapeutics Inc

-0.0039 (-5.99%)
Last Updated: 10:36:25
Delayed by 15 minutes


Draw Mode:

Volume 9,172,293
Bid Price 0.0612
Ask Price 0.0617
News -
Day High 0.0664


52 Week Range


Day Low 0.0612
Share Name Share Symbol Market Stock Type
Avalo Therapeutics Inc AVTX NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.0039 -5.99% 0.0612 10:36:25
Open Price Low Price High Price Close Price Previous Close
0.0664 0.0612 0.0664 0.0651
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
6,573 9,172,293 US$ 0.0647412 US$ 593,825 - 0.0612 - 6.0865
Last Trade Type Quantity Price Currency
10:36:32 2 US$ 0.0616 USD

Avalo Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
563.68M 192.38M - 18.05M -41.66M -0.22 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Avalo Therapeutics News

Date Time Source News Article
11/16/202306:15Edgar (US Regulatory)Form 8-K - Current report
11/09/202306:21Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/09/202306:04Edgar (US Regulatory)Form 8-K - Current report
11/09/202306:00GlobeNewswire Inc.Avalo Reports Third Quarter 2023 Financial Results and..
10/31/202306:21Edgar (US Regulatory)Form 8-K - Current report
10/31/202306:00GlobeNewswire Inc.Avalo Completes Divestiture of AVTX-800 Series
10/19/202315:15Edgar (US Regulatory)Form ARS - Annual Report to Security Holders
10/19/202315:06Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting..
10/19/202315:01Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statements
10/17/202315:02Edgar (US Regulatory)Form 8-K - Current report
10/05/202315:02Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statements
9/26/202306:04Edgar (US Regulatory)Form 8-K - Current report
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No AVTX Message Board. Create One! See More Posts on AVTX Message Board See More Message Board Posts

Historical AVTX Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.09090.09450.06120.07506618,630,464-0.0297-32.67%
1 Month0.10390.120.06120.092119818,887,497-0.0427-41.1%
3 Months0.09150.2960.06120.146869679,801,587-0.0303-33.11%
6 Months2.884.710.06120.150679640,403,706-2.82-97.88%
1 Year5.626.08650.06120.153100520,218,196-5.56-98.91%
3 Years2.877.130.06120.18014099,092,898-2.81-97.87%
5 Years2.877.130.06120.18014099,092,898-2.81-97.87%

Avalo Therapeutics Description

Avalo Therapeutics Inc is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases. Its pipeline consists of product candidates advancing in development with ongoing clinical programs: AVTX-002, AVTX-007, and AVTX-006.

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 |